hing conversations performed helped the cancer survivors to process many of these difficult thoughts and feelings.
  The P2Y12 platelet receptor inhibitor ticagrelor is widely used in patients following acute coronary syndromes or in those who have received coronary stents. Bentracimab is a monoclonal antibody-based reversal agent that is being formally evaluated in a Phase 3 clinical trial. Here, we probe the knowledge, attitudes, and practice patterns of cardiac surgeons regarding their perioperative management of ticagrelor and potential application of a ticagrelor reversal agent.
 
  A questionnaire was developed by a working group of cardiac surgeons to inquire into participants' practices and beliefs regarding ticagrelor and disseminated to practicing, Canadian-trained cardiac surgeons.
 
  A total of 70 Canadian-trained cardiac surgeons participated. Bleeding risk was identified as the most significant consideration when surgically revascularizing ticagrelor-treated patients (90%). There is variability in the duration of withholding ticagrelor before coronary artery bypass graft procedure in a stable patient; 44.3% wait 3 days and 32.9% wait 4 days or longer. Currently, 15.7% of cardiac surgeons prophylactically give platelet transfusions and fresh frozen plasma intraoperatively following protamine infusion in patients who have recently received ticagrelor. Interestingly, 47.1% of surveyed surgeons were aware of a reversal agent for ticagrelor, 91.4% of cardiac surgeons would consider utilizing a ticagrelor reversal agent if available, and 51.4% acknowledged that the introduction of such an agent would be a major advance in clinical practice.
 
  The present survey identified ticagrelor-related bleeding as a major concern for cardiac surgeons. Surgeons recognized the significant unmet need that a ticagrelor reversal agent would address.
 The present survey identified ticagrelor-related bleeding as a major concern for cardiac surgeons. Surgeons recognized the significant unmet need that a ticagrelor reversal agent would address.
  Pulmonary surfactant protein A (SP-A) in the respiratory tract plays an important role in host. In the present, we assessed the association between SP-A gene polymorphism and allergic rhinitis.
 
  Using a case-control design, we compared the genotype frequencies of SP-A rs1965708 between allergic rhinitis patients and healthy control group. Genotyping was performed using real-time quantitative PCR-based molecular identification methods.  https://www.selleckchem.com/products/5-ethynyluridine.html  Univariate and multivariate logistic regression were performed to quantitatively assess the association between rs1965708 polymorphism and allergic rhinitis, and the odds ratio (OR) and 95% confidence interval (CI) were also calculated.
 
  500 patients with allergic rhinitis and 500 healthy controls were included in the study. Compared with the CC genotype, we found that AA genotype of rs1965708 could increase the allergic rhinitis risk in the univariate analysis (OR=2.63, 95% CI 1.56-4.54, p=0.000). For dominant model, we found no significant difference in the dominant model (OR=1.14, 95% CI 0.86-1.52, p=0.367). In the recessive model, the CC genotype could elevate the risk of allergic rhinitis compared with CC+AA genotype (OR=2.70, 95% CI 1.61-4.54, p=0.000). Similar results were also found in the allele model (OR=1.28, 95% CI 1.07-1.54, p=0.008). Interactions between rs1965708 AA or AC and smoking increased the allergic rhinitis risk.
 
  The rs1965708 variants of SP-A gene polymorphism are associated with allergic rhinitis, and the A allele could increase the allergic rhinitis risk. The AA SNP variants that interact with smoking may alter the susceptibility to allergic rhinitis.
 The rs1965708 variants of SP-A gene polymorphism are associated with allergic rhinitis, and the A allele could increase the allergic rhinitis risk. The AA SNP variants that interact with smoking may alter the susceptibility to allergic rhinitis.
  The renin-angiotensin-aldosterone system (RAAS), when chronically activated, is harmful and RAAS-suppressive drugs are beneficial in the treatment of congestive heart failure (CHF). Mineralocorticoid receptor antagonists are widely used in the treatment of CHF in people.
 
  To determine if a mineralocorticoid receptor antagonist (spironolactone) is beneficial and safe in CHF due to myxomatous mitral valve disease (MMVD) of varying severity, we hypothesized that, when combined with furosemide, a combination product (S+BNZ) containing the ACE inhibitor (ACE-I), benazepril, and spironolactone, would be superior to benazepril alone.
 
  Five hundred and sixty-nine client-owned dogs, with MMVD and CHF (ACVIM Stage C) of ≤10-days' duration.
 
  After initial stabilization, dogs were randomized into a positive-controlled, double-blind, multicenter trial, to receive furosemide plus S+BNZ or furosemide plus benazepril. The primary outcome variable was the percentage of dogs reaching cardiac endpoint before Day 360. Cardiac endpoint was defined as cardiac death or euthanasia, recurrence of pulmonary edema, necessity for nonauthorized cardiac drug(s) or a furosemide dosage >8mg/kg/d.
 
  A significantly lower percentage of dogs treated with S+BNZ reached the primary outcome variable by Day 360 (OR=0.56; 95% CI, 0.32-0.98; P=.04) and risk of dying or worsening from cardiac causes, was significantly reduced (HR=0.73; 95% CI=0.59-0.89, P=.002) vs benazepril alone. Adverse events, potentially associated with treatment, were rare and equal between groups.
 
  The combination of S+BNZ is effective, safe, and superior to benazepril alone, when used with furosemide for the management of mild, moderate or severe CHF caused by MMVD in dogs.
 The combination of S+BNZ is effective, safe, and superior to benazepril alone, when used with furosemide for the management of mild, moderate or severe CHF caused by MMVD in dogs.Aging brings about notable changes in sociality, with an increasing focus on essential partners in both humans and nonhuman primates. Several studies have shown that older nonhuman primates have fewer social partners and shift their types of interactions. The majority of these studies, however, involved only female individuals. Much less is known about the trajectory of social aging in males. We collected 2180 h of focal observation data in a large age-heterogeneous sample of 34 male and 50 female Barbary macaques (Macaca sylvanus; age range 5-30 years) living in two social groups at the outdoor enclosure at La Forêt des Singes in Rocamadour (France). To track age-related changes in social engagement of both sexes, we used classical behavioral and social network analysis to measure age-related variation in the number of partners, the frequency of affiliative interactions, and the position in the social network (eigenvector centrality and local clustering coefficient). We found that females were more central in most social network metrics than males, that is, had more social partners and were more engaged in affiliative interactions than males.